Brexit up­date

The Hindu Business Line - - PULSE -

The Euro­pean Medicines Agency’s (EMA) Brexit pre­pared­ness busi­ness con­ti­nu­ity plan (BCP) en­tered its third phase on Oc­to­ber 1 2018, as an­nounced at the be­gin­ning of Au­gust 2018. The tem­po­rary sus­pen­sion or re­duc­tion of ad­di­tional ac­tiv­i­ties in this phase al­lows the Agency to safe­guard core ac­tiv­i­ties re­lated to the eval­u­a­tion and su­per­vi­sion of medicines while the Agency pre­pares for the con­se­quences of the United King­dom’s (UK) exit from the Euro­pean Union (EU) — both in terms of the im­pact on the

Agency’s op­er­a­tions, as well as its phys­i­cal move to Amsterdam. It will also help the Agency cope with an­tic­i­pated staff loss, the EMA said. “EMA will now tem­po­rar­ily sus­pend or scale back ad­di­tional ac­tiv­i­ties to en­sure that re­sources can be re­de­ployed so that its core ac­tiv­i­ties can con­tinue with­out in­ter­rup­tion and to the same qual­ity,” said Noël Wathion, EMA’s Deputy Ex­ec­u­tive Di­rec­tor. “Over the next few months, EMA will con­tinue to care­fully mon­i­tor staff in­ten­tions to re­lo­cate and the an­tic­i­pated im­pact on its ac­tiv­i­ties whilst plan­ning for the crit­i­cal time pe­riod when the Agency will be mov­ing to its new premises in Amsterdam.”

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.